The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Resmed Inc shares valued at $2,011,910 were sold by Farrell Michael J. on Jun 09 ’25. At $251.21 per share, Farrell Michael J. sold 8,009 shares. The insider’s holdings dropped to 455,503 shares worth approximately $114.88 million following the completion of this transaction.
Also, Farrell Michael J. purchased 8,009 shares, netting a total of over 2,018,268 in proceeds.
Before that, FARRELL PETER C had sold 2,000 shares from its account. In a trade valued at $494,640, the Director traded Resmed Inc shares for $247.32 each. Upon closing the transaction, the insider’s holdings decreased to 2,000 shares, worth approximately $17.46 million.
As published in their initiating research note from Morgan Stanley on March 19, 2025, Resmed Inc [RMD] has been an Overweight and the price target has been revised to $280. Analysts at Morgan Stanley started covering the stock with ‘”an Overweight”‘ outlook in a report released in mid March. As of January 16, 2025, Goldman has initiated its “Buy” rating for RMD. Earlier on January 10, 2025, Piper Sandler initiated its rating. Their recommendation was “a Neutral” for RMD stock.
Analyzing RMD Stock Performance
During the last five days, there has been a surge of approximately 1.01%. Over the course of the year, Resmed Inc shares have jumped approximately 10.28%. Shares of the company reached a 52-week high of $263.05 on 01/30/25 and a 52-week low of $199.92 on 04/07/25.
Support And Resistance Levels for Resmed Inc (RMD)
According to the 24-hour chart, there is a support level at 250.91, which, if violated, would cause prices to drop to 249.62. In the upper region, resistance lies at 252.86. The next price resistance is at 253.51. RSI (Relative Strength Index) is 63.46 on the 14-day chart, showing neutral technical sentiment.
